Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗

October 13, 2023

Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.

Via Benzinga

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More ↗

October 06, 2023

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares

Via Benzinga

Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment ↗

October 03, 2023

Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the

Via Benzinga

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares ↗

October 03, 2023

NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

What 11 Analyst Ratings Have To Say About Cybin ↗

September 01, 2023

Via Benzinga

6 Analysts Have This to Say About Cybin ↗

August 15, 2023

Via Benzinga

Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression ↗

September 26, 2023

Clinical-stage psychedelics biotech Cybin Inc.

Via Benzinga

Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗

September 26, 2023

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

Via Benzinga

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression ↗

September 21, 2023

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...

Via Benzinga

Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

September 20, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.

Via Benzinga

Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket ↗

September 19, 2023

Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 19, 2023

Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning!

Via InvestorPlace

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗

September 18, 2023

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

Via Benzinga

The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023 ↗

September 14, 2023

Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy.

Via InvestorPlace

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT ↗

September 05, 2023

The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and...

Via Benzinga

Topics Intellectual Property

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗

August 31, 2023

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...

Via Benzinga

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M ↗

August 29, 2023

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9...

Via Benzinga

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗

August 28, 2023

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

Via Benzinga

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety ↗

August 28, 2023

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

Via Benzinga

Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M ↗

August 24, 2023

Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million...

Via Benzinga

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗

August 21, 2023

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds

Via Benzinga

Topics Cannabis Economy

Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library ↗

August 16, 2023

Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs

Via Benzinga

Topics Intellectual Property

Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic ↗

August 14, 2023

Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023:

Via Benzinga

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M ↗

August 04, 2023

Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cybin Inc. Common Shares (NY:CYBN)

Headline News about Cybin Inc. Common Shares

Starting at $3.75/week.

Subscribe Today